Why Canadian Cannabis Producers Are Racing Toward EU-GMP Certification

Weak domestic prices and a fixed $1-per-gram excise floor have squeezed Canadian margins to the breaking point. EU-GMP certification opens the export markets where the math works again. Here is why it matters, what certification takes, and where Twister fits in.

Why are Canadian producers chasing EU-GMP certification?

EU-GMP certification is the regulatory requirement for selling medical cannabis into European markets like Germany, and for a growing number of Canadian producers it has become the difference between a viable business and a slow squeeze. Canada supplied 53% of Germany's medical cannabis flower imports in the first quarter of 2026. That is not a coincidence, and it is not exactly a victory lap for the Canadian industry either.

For these producers, exports are no longer just a nice growth channel. They are becoming the business case. And for anyone trying to reach Europe, EU-GMP certification is the ticket in.

To understand why, you only need to look at two things: what flower sells for in Canada, and what the government takes off the top before producers see a penny.

1. The domestic math stopped working

When Canada legalized cannabis in 2018, the excise tax framework was built around a very different market. At the time, dried flower was expected to wholesale around $10 per gram. The duty was set as the greater of $1 per gram or 10% of the producer's selling price. At 2018 prices, those two formulas were roughly in the same ballpark.

Then the market changed.

Canada licensed nearly 1,000 producers to serve a population of about 40 million people. Inventory piled up, bulk wholesale pricing collapsed, and by 2023, average wholesale flower prices had fallen to about $1.07 per gram.

Prices recovered slightly in 2024, then firmed again in early 2025 as export demand picked up. But as producers responded with more production, pricing started sliding again. By September and October, wholesale prices were back near a two-year low of $1.22 per gram.

For the full year 2025, freshly harvested flower averaged $1.51 per gram. Flower over a year old averaged just $0.96 per gram. Even stronger, higher-potency lots were mostly concentrated in the $2.00 to $2.75 range. The Canadian Cannabis Exchange forecasts the 2026 average at $1.41 per gram, potentially strengthening to around $1.57 by December, with one major caveat: exports are now the main pressure valve keeping domestic pricing from falling further.

That is the first problem: cannabis pricing never reached the projected $10 per gram range. The second problem compounds it: the $1 per gram excise floor never moved.

That is not a small tax problem. That is a business model problem.

For many Canadian LPs, excise tax has become the largest line item on the P&L. Bigger than cultivation labour, packaging, or energy. The results have been ugly: hundreds of millions in excise arrears, creditor protection filings, surrendered licences, and commercial producers exiting the market entirely. Licensed producers owed the Canada Revenue Agency more than $279 million in excise arrears as of mid-2023, spread across more than 130 businesses.

When the CRA escalated to garnishing cash from delinquent producers, BZAM filed for creditor protection within days, carrying massive unpaid tax bills. Craft producer Tantalus Labs cited an excise bill three times the total salary of its 65-person team as a major factor in its own insolvency. A recent academic study of 36 LPs found nine filed for insolvency between fiscal 2022 and 2024, and only 14.3% of the companies analyzed posted positive net income in fiscal 2023. The researchers calculated that figure would double if excise were genuinely capped at 10% of sales.

Ottawa has signalled that excise reform is "on the table," including the possibility of capping duty at 10% of wholesale price. But producers cannot run a business on a signal. They need margin now.

That is where exports come in.

2. Exports change the equation

Here is the part that explains the EU-GMP rush: excise duty applies when product enters the Canadian duty-paid market. Exported product does not enter that market, which means no Canadian excise duty is owed. As Decibel Cannabis's chief revenue officer put it, on exports "your gross revenue becomes your net revenue."

For producers who can export, the math changes immediately. Revenue that would have been crushed by domestic excise suddenly has room to breathe.

Then you add the price difference. In Germany, imported dried flower has recently ranged from roughly €0.60 to €3.48 per gram, or about CAD $1.00 to $5.60. Certified, finished flower sits toward the stronger end of that range.

So instead of selling flower domestically for roughly $1.20 to $1.50 per gram, a producer with access to Germany may be looking at something closer to $3.50 to $5.50 per gram.

Demand is there too. Germany's April 2024 cannabis reform created a wave of medical cannabis demand that domestic production cannot come close to supplying. Germany has just three licensed domestic producers serving a population of roughly 84 million people. In Q1 2026 alone, Germany imported more than 50,000 kilograms of medical cannabis flower, and Canada supplied 53% of it.

That is the opportunity. But there is a catch: none of it moves without EU-GMP.

3. EU-GMP is the price of admission

If a cannabis producer wants to access the European medical market, the product needs to meet EU-GMP standards.

Canada's domestic Good Production Practices standard, or GPP, is what Canadian producers need to maintain to supply the domestic market. For exports into Europe, GPP is not enough. GPP helps ensure a clean facility and basic contaminant testing. EU-GMP goes much further. It is built around pharmaceutical-grade manufacturing, documentation, repeatability, and control.

That difference matters. EU-GMP is not a few extra forms or a quick facility polish. It is a full systems upgrade.

Producers need to prove that their process is repeatable and can deliver a quality outcome, batch after batch, under documented and controlled conditions. Making the same cannabis with identical cannabinoid content and terpene profiles is impossible batch after batch, this being an organically grown plant. But the process in which the plant is produced is repeatable. That includes quality systems, personnel training, production controls, facility standards, equipment documentation, cleaning validation, and quality control.

It is a big lift. But that is also why it creates an advantage for producers who get there early and execute well.

Tilray's Nanaimo, BC facility became the first medical cannabis producer in North America to achieve GMP certification to European Medicines Agency standards in December 2016, and Twister was part of that journey. That same year, Tilray completed the first legal export of medical cannabis from North America to the EU. Three years later, only a handful of Canadian LPs had followed.

Those early investments are part of the reason Canadian producers are still helping anchor the export market today.

4. What it takes to get EU-GMP certified

Every certification path is different, but most producers will move through the same basic stages.

Gap analysis

The first step is comparing current operations against EudraLex Volume 4, the EU's GMP guideline framework. For cannabis, Annex 7 is especially important because it covers herbal medicinal products.

This review identifies gaps across quality management, personnel, premises, equipment, documentation, production, and quality control. In plain terms: where are you today, where does EU-GMP require you to be, and what needs to change?

Quality management system build-out

EU-GMP is documentation-heavy. Producers need validated SOPs, batch records, deviation systems, CAPA processes, change control, and the right qualified person structure to satisfy European inspectors.

This is where a lot of the work happens. It is not enough to have a good process. You need to prove the process exists, prove the team follows it, and prove that deviations are managed correctly when something changes.

Facility and equipment upgrades

Premises and equipment need to meet pharmaceutical expectations. That means cleanable surfaces, controlled environments, validated cleaning procedures, and documented materials of construction.

For post-harvest equipment, this is critical. Any surface that touches product needs to be traceable to compliant materials, typically pharmaceutical-grade stainless steel or other documented product-contact materials.

Training and qualification

Staff need to be trained to GMP standards, and that training needs to be documented. Process validation runs are also required to demonstrate that production can deliver consistent results batch after batch.

In other words, EU-GMP is not just about the facility. It is about the people, the process, and the proof.

Sponsoring importer and inspection

EU-GMP certification is issued by an EU national competent authority. That inspection is typically connected to an EU-based importer or distributor relationship.

Inspectors will look at everything from the gap analysis forward: the facility, equipment, documentation, procedures, training records, production controls, and quality systems.

Ongoing compliance

Certification is not a one-and-done event. Producers need to maintain the standard through re-inspections, continuous compliance, and tighter scrutiny around how cannabis moves through the supply chain.

German regulators have already issued non-compliance citations that suggest enforcement will only get tighter. For most producers, a realistic certification timeline is 12 to 24 months, and costs can easily reach seven figures.

That is exactly why certified producers who execute well can capture outsized returns.

5. Where Twister fits: post-harvest equipment built for GMP from the start

Post-harvest equipment sits directly inside the EU-GMP perimeter. Trimming, sorting, conveying, and grading equipment all touch product. That means materials of construction, cleanability, and documentation are not nice-to-haves.

They are audit requirements.

This is where equipment selection can either speed up your certification path or slow it down.

Twister post-harvest equipment is already used in EU-GMP certified facilities today. That did not happen by accident. Twister helped pave the way for cannabis equipment in GMP environments.

When Tilray pursued GMP certification at its Nanaimo facility, the first EU-GMP licensed cannabis facility in North America, the Twister T4 was their trimmer of choice, and our team customized their machines to meet the standard. That included the introduction of the salt-bath nitrided bed-knife and helix blades for hardened, corrosion-resistant cutting surfaces, standard in all of Twister's equipment since 2018 (and copied by many competitor products since), along with stainless steel components throughout the product contact path.

That engineering work was done alongside one of the producers that helped write the playbook for North American EU-GMP certification.

That same work continued as we supported EU-GMP certification of many other producers from around the world, for our entire line of products. Not only do producers lean on Twister for our equipment and processing knowledge, we can support with documentation, such as URS, DQ, IQ, OQ and PQ, and have worked alongside many EU-GMP consultants.

For producers starting their own certification journey, that history matters. Equipment with a proven track record in certified facilities, supported by materials documentation that can go into an inspector's binder, removes one of the slower and more expensive workstreams from the gap-closure plan.

That does not make certification easy. But it does mean you are not starting from scratch.

6. The window is open, but it will not stay wide forever

Every export business case needs one important warning: Europe is starting to look like Canada a few years ago.

As certified supply increases, pricing pressure will follow. German pharmacy prices for flower already fell by roughly a third over 2025 as more certified product entered the market. The EU-GMP premium is still real, but it is compressing.

That means the next phase will not be won by certification alone. Eventually, more producers will hold the same certificate. The winners will be the producers who can protect yield, reduce labour cost per gram, preserve flower quality, and deliver consistent pharmaceutical-grade output at scale.

That is a post-harvest problem.

And it is the same problem Twister has been engineering against since before the first North American EU-GMP cannabis certificate was issued.

EU-GMP certification FAQ

*All pricing is reported in CAD and based on Canadian Cannabis Exchange (CCX) wholesale flower data, unless otherwise noted. German import figures are from Germany's Federal Institute for Drugs and Medical Devices (BfArM), Q1 2026.